Loading
Life sciences · Journal article
npj Breast Cancer · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Breast cancer stem-like cells (BCSCs) drive metastasis and therapy resistance, yet selective therapeutics to eliminate this quiescent population are lacking. We explored the potential of mammalian orthoreovirus (MRV) as an oncolytic agent against paclitaxel-resistant (TaxR) ER+ BCSCs. Through serial passaging of the MRV strain T1L in TaxR tumorspheres, we developed novel viral clones (T1L SP B and C) with enhanced oncolytic potency. Notably, these evolved clones demonstrated superior killing of TaxR BCSCs despite reduced infectivity and viral protein synthesis compared to the parental strain. Whole-genome sequencing identified specific viral protein mutations correlating with this enhanced potency. Mechanistically, while all strains induced apoptosis, T1L SP B triggered markers of immunogenic cell death (ICD), significantly increasing the release of the damage-associated molecular pattern (DAMP) extracellular ATP. Our findings demonstrate that directed viral evolution can generate potent oncolytic agents capable of both eliminating resistant BCSCs and potentially stimulating anti-tumor immunity.